Blood test may predict best osteoporosis drug for each woman
NCT ID NCT07616401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find small molecules called microRNAs in the blood that can predict how well two osteoporosis drugs (romosozumab and abaloparatide) work in postmenopausal women. Researchers will measure bone density and blood markers over 12 months in 42 women. The goal is to help doctors choose the most effective treatment for each patient.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENOPAUSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Ospedale Galeazzi Sant'Ambrogio
NOT_YET_RECRUITINGMilan, Lombardy, Italy
-
Istituto Auxologico Italiano IRCCS
RECRUITINGMiano, Lombardy, 20149, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can discarded bone reveal the secrets to stronger bones?
- Could a common diabetes drug weaken your bones?
- A tastier calcium chew might boost bone Health—But does it work?
- Exercise program aims to steady the stance of osteoporosis patients
- Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?
- Gut bacteria may soothe menopause symptoms — a trial puts it to the test